Behavioral and biochemical investigations of bupropion metabolites

European Journal of Pharmacology

Volumn 474, Issue 1, 2003, Pages 85-93

  Bondarev, Mikhail L ^a   Bondareva, Tatiana S ^a   Young, Richard ^a   Glennon, Richard A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Amphetamine; Bupropion; Bupropion metabolite; Hydroxybupropion; Nicotine; Threohydrobupropion

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; DOPAMINE TRANSPORTER; DRUG METABOLITE; HYDROXYBUPROPION; NICOTINE; NICOTINIC RECEPTOR; NORADRENALIN TRANSPORTER; RECEPTOR SUBUNIT; RUBIDIUM 86; THREO HYDROBUPROPION; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISCRIMINATION; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; ISOMER; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT; STIMULATION; SUBSTITUTION REACTION; TRAINING;

EID: 0142043471     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02010-7     Document Type: Article

References (34)

1. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., Richelson E., Sulser F. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry. 56:1995;395-401.
2. Chance W.T., Murphin D., Krynock G.M., Rosecrans J.A. A desription of the nicotine stimulus and tests of its generalization to amphetamine. Psychopharmacology. 55:1977;19-26.
3. Cooper T.B., Suckow R.F., Glassman A. Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. J. Pharm. Sci. 73:1984;1104-1107.
4. DeVane C.L., Laizure S.C., Stewart J.T., Kolts B.E., Ryerson E.G., Miller R.L., Lai A.A. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J. Clin. Psychopharmacol. 10:1990;328-332.
5. Evans S.M., Johanson C.E. Amphetamine-like effects of anorectics and related compounds in pigeons. J. Pharmacol. Exp. Ther. 241:1987;817-825.
6. Fang Q.K., Han Z., Grover P., Kessler D., Senanayake C.H., Wald A.A. Rapid access to enantiopure bupropion and its major metabolite by stereospecific nucleophilic substitution on an α-ketotriflate. Tetrahedron: Asymmetry. 11:2000;3659-3663.
7. Fang, Q.K., Senanayake, C.H., Grover, P., 2001. Bupropion metabolites and methods of their synthesis and uses. World Patent 01/62257, August 30.
8. Finney D. Probit Analysis. 1952;Cambridge Univ. Press, London.
9. Fryer J.D., Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 288:1999;88-92.
10. Glennon R.A., Young A.M., Martin B.R., DalCason T.A. Methcathinone ("Cat"): an enantiomeric potency comparison. Pharmacol. Biochem. Behav. 50:1995;601-606.
11. Horst W.D., Preskorn S.H. Mechanism of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J. Affect. Dis. 51:1998;237-254.
12. Hsyu P.H., Singh A., Giargiari T.D., Dunn J.A., Ascher J.A., Johnston J.A. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J. Clin. Pharmacol. 37:1997;737-743.
13. Kelley J.L., Musso D.L., Boswell G.E., Soroko F.E., Cooper B.R. (2S,3S,5R)-2-(3,5-Difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake. J. Med. Chem. 39:1996;347-349.
14. Lai A.A., Schroeder D.H. Clinical pharmacokinetics of bupropion: a review. J. Clin. Psychiatry. 44(5, Part 2):1983;82-84.
15. Martin P., Massol J., Colin J.N., Lacomblez L., Puech A.J. Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry. 23:1990;187-194.
16. 3H]norepinephrine. J. Pharmacol. Exp. Ther. 302:2002;1113-1122.
17. Morgan, P.F., Partridge, J.J., 1999. Pharmaceutically active morpolinol. World Patent 99/37305, July 29.
18. Munzar P., Goldberg S.R. Dopaminergic involvement in the discriminative stimulus effects of methamphetamine in rats. Psychopharmacology. 148:2000;209-216.
19. Musso D.L., Mehta N.B., Soroko F.E., Ferris R.M., Hollingsworth E.B., Kenney B.T. Synthesis and evaluation of the activity of the enantiomers of bupropion. Chirality. 5:1993;495-500.
20. Porsolt R.D., Pawalec C., Jalfre M. Use of a drug discrimination procedure to detect amphetamine-like effects of antidepressants. Colpaert F.C., Slangen J.L. Drug Discrimination: Applications in CNS Pharmacology. 1982;193-202 Elsevier, Amsterdam.
21. Posner J., Bye A., Dean K., Peck A.W., Whiteman P.D. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur. J. Clin. Pharmacol. 29:1985;97-103.
22. Rotzinger S., Bourin M., Akimoto Y., Coutts R.T., Baker G.B. Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell. Mol. Neurobiol. 19:1999;427-442.
23. Sanchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19:1999;467-489.
24. Schroeder D.H. Metabolism and kinetics of bupropion. J. Clin. Psychiatry. 44(5, Part 2):1983;79-81.
25. Slemmer J.E., Martin B.R., Damaj M.I. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295:2000;321-327.
26. Stolerman I.P., Garcha H.S., Pratt J.A., Kumar R. Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology. 84:1984;413-419.
27. Suckow R.F., Smith T.M., Perumal A.S., Cooper T.B. Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs. Drug Metab. Dispos. 14:1986;692-697.
28. Suckow R.F., Zhang M.F., Cooper T.B. Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography. Biomed. Chromatogr. 11:1997;174-179.
29. Sweet R.A., Pollock B.G., Kirshner M., Wright B., Altieri L.P., DeVane C.L. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J. Clin. Pharmacol. 35:1995;876-884.
30. Welch R.M., Lai A.A., Schroeder D.H. Pharmacological significance of the species differences in bupropion metabolism. Xenobiotica. 17:1987;287-298.
31. Wiley J.L., Lavecchia K.L., Martin B.R., Damaj M.I. Nicotine-like discriminative stimulus effects of bupropion in rats. Exp. Clin. Psychopharmacol. 10:2002;129-135.
32. Xiao Y., Meyer E.L., Thompson J.M., Surin A., Wroblewski J., Kellar K.J. Rat alpha3/beta4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function. Mol. Pharmacol. 54:1998;322-333.
33. Young R.C. Hydroxylated metabolites of antidepressants. Psychopharmacol. Bull. 27:1991;521-523.
34. Young R., Glennon R.A. Nicotine and bupropion share a similar discriminative stimulus effect. Eur.J. Pharmacol. 443:2002;113-118.